KLK3 and neoplasm: Current clinical models, reliant on serum prostate-specific antigen (PSA) levels, Gleason scores, and TNM staging, suffer from limited predictive accuracy, failing to capture the complex tumor biology of advanced PCa [2,3,4,5].